Close Menu

People in the News

May 23, 2019

Douglas Clark

TriCore Reference Laboratories has named Douglas Clark chief medical officer, effective September 2019. Clark is already serving as chairman of TriCore's board of directors. He most recently served as pathology department chairman and professor at the University of New Mexico. Prior to that, he served as director of the division of cytopathology at The Johns Hopkins Medical Institutions. 

May 21, 2019

Sangeeta Bhorade

Veracyte has hired Sangeeta Bhorade as medical director of pulmonology to lead medical affairs for the firm's pulmonology products. Bhorade joins Veracyte from Northwestern University Feinberg School of Medicine, where she served as professor of medicine and medical director of the lung transplant program. Prior to Northwestern, Bhorade served as medical director of the lung transplant program at the University of Chicago Medical Center. She has also served as associate medical director of lung transplant at Loyola University Chicago.

May 09, 2019

Sun Kim

Centogene has appointed Sun Kim as its chief strategy and investor relations officer. Prior to Centogene, Kim served as head of corporate strategy at Shire Pharmaceuticals. Before Shire, Kim worked at Alcon for six years, where he served in multiple roles including head of strategy and general manager of Alcon Singapore.

May 07, 2019

David Parker, Mike Evans

David Parker, a general partner in Ampersand Capital Partners, and Mike Evans, operating partner at Ampersand, have joined the board of Dutch firm Genome Diagnostics, which said this week that Ampersand invested an undisclosed amount in the firm. Ampersand, as a result, became minority shareholders in GenDx. 

Apr 30, 2019

Jimmy Lin

Freenome has appointed Cheng-Ho Jimmy Lin, as its chief scientific officer, with responsibilities for scientific strategy, research operations, and growing the company’s scientific team. Prior to joining the private sector, Lin led the intramural clinical genomics program at the National Cancer Institute at the National Institutes of Health. At Johns Hopkins and Washington University in St Louis, he also spearheaded the computational analyses of exome sequencing studies in multiple cancer types.

Lin's most recent role was CSO for oncology at Natera, where he drove the development and launch of that firm's blood-based assays for cancer monitoring residual disease detection. He holds an MD and PhD in cellular and molecular medicine and a Masters in health sciences in bioinformatics from Johns Hopkins School of Medicine.

Apr 25, 2019

Alfred Bowie Jr.

Veracyte has named Alfred Bowie Jr. as vice president of corporate and business development where he will lead the company's strategic planning process. Previously, Bowie led strategic planning, corporate development and competitive intelligence at Foundation Medicine, a Roche subsidiary, and served in corporate and business development positions at Tecan Group and Danaher Corporation. He has also worked in management consulting at the Boston Consulting Group.

Apr 24, 2019

Andrew Last

Bio-Rad Laboratories has appointed Andrew Last as executive VP and chief operating officer, responsible for all operating functions of the company on a global basis. Last was most recently CCO at Berkeley Lights and prior to that he served as COO at Intrexon. He was executive VP and COO at Affymetrix between 2010 and 2016, and has also previously held senior positions at Becton Dickinson, Applied Biosystems, Incyte Genomics, and Monsanto.

Apr 23, 2019

Bahija Jallal

Guardant Health has appointed Bahija Jallal to its board of directors, effective April 17. Jallal has served as the CEO of Immunocore Limited, a T cell receptor biotechnology company, since January 2019. Prior to that she served as executive VP of AstraZeneca and was president of MedImmune, a subsidiary of AstraZeneca, after holding various other research and development positions at the firm. Jallal is a member of the board of trustees at Johns Hopkins University and of UMB Health Sciences Research Park. She has also served as a past president of the Association for Women in Science.

Apr 23, 2019

Joseph Frendo

Caris Life Sciences announced Joseph Frendo has joined the company as chief operations officer. He was senior vice president of PBM Operations at CVS health. Prior to that, he held various management positions at Medco Health Solutions. In his role at Caris, Frendo will direct technical and clinical staff operations and guide strategies to advance quality and optimize efficiences across the firm, Caris said. 

Apr 18, 2019

Ori Karev

Ori Karev has joined Precipio as chief strategy officer. Karev was formerly CEO of UnitedHealthcare Global, the international division of United Healthcare. He also previously worked for Ernst & Young. An attorney by training, Karev has more than 30 years of experience in the healthcare, insurance, and mobility industries, Precipio said.

Apr 17, 2019

Carsten Ullrich

Centogene has appointed Carsten Ullrich its director of artificial intelligence. He will direct the firm's use of AI to enhance diagnostic effectiveness and quality, and to discover new insights, accelerate biomarker development, and drive solutions for drug firms. Ullrich was most recently associate head of a research lab and senior researcher at the German Research Center for Artifidal Intelligence. 

Apr 15, 2019

Amy Winslow

Amy Winslow was named president of BioPorto Diagnostics, the US subsidiary of BioPorto. She will be responsible for building and leading the US operation as it prepares to launch the NGAL Test for identifying acute kidney injury before permanent damage occurs. The company expects the US Food and Drug Administration to clear the test later this year. Winslow was most recently president and CEO of Magellan Diagnostics, an independent business unit of Meridian Bioscience. Prior to that, she was vice president of marketing for Athena Diagnostics. 

Apr 12, 2019

Axel Sjöblad

SenzaGen has appointed Axel Sjöblad its CEO, effective June 17. He replaces Anki Malmborg Hager who was CEO for five years and is becoming a member of the firm's board. Sjöblad was most recently CEO of BioGaia. Before that, he was president of sales and service North Europe and CEO of Getinge Sverige. He also was regional vice president Northern European markets at Gambro. Based in Sweden SenzaGen develops in vitro assays for immunotoxicity testing.

Apr 10, 2019

Gary Winer

German speciality diagnostics company Orgentec Diagnostika's board has appointed Gary Winer the firm's president and CEO, effective immediately. Winer has held senior leadership positions with companies including AbbVie, Abbott Laboratories, and Pfizer. At Abbott, he managed the firm's diagnostics business in the US, Canada, and Latin America before he was promoted to lead Abbott Japan. 

Apr 10, 2019

Andrew Connerty

Andrew Connerty has been appointed vice president of quality assurance and regulatory affairs for First Light Diagnostics. He has more than 25 years of quality systems management expertise at a strategic and tactical level and has worked at Johnson & Johnson, Confluent Surgical, SeraCare Life Sciences, RainDance Technologies, and Bio-Rad Laboratories. 

Apr 05, 2019

Karen Koski

Karen Koski has been appointed the chief business officer for Specific Diagnostics, effective April 8. She was previously with Oxford Immunotec as vice president of strategy and investor relations. Prior to that, she was a director and senior equity analyst at BTIG. 

Apr 03, 2019

Ilan Daskal

Bio-Rad Laboratories has appointed Ilan Daskal as executive vice president and CFO. Daskal previously served as CFO of Lumileds, a lighting manufacturer formed in 1999 as a joint venture between Philips Lighting and Agilent Technologies. He will replace Christine Tsingos, who is retiring.

Apr 03, 2019

Parag Mallick

Parag Mallick has been appointed to the scientific board of Oncimmune Holdings. He is an associaate professor of radiology at Stanford University and a member of the Canary Center for Cancer Early Detection. His research focuses on approaches using big data, mathematical modeling, and machine learning to discover cancer biomarkers for personalized and predictive medicine. 

Apr 02, 2019

Michael Deppe

Quest Diagnostics said in a document filed with the US Securities and Exchange Commission that Michael Deppe was elected vice president, corporate controller and chief accounting officer and the company's principal accounting officer. Deppe joined Quest in 1998 and has served in various account and finance leadership positions, including president of finance-enterprise operation and IT from August 2015 to March 2019. Before joining the company, he started his career at PricewaterhouseCoopers. 

Apr 02, 2019

Flemming Ornskov

Flemming Ornskov was appointed to Centogene's supervisory board and elected its non-executive chairman, effective April 1. He most recently was CEO of Shire. Prior to that, he held senior positions at several pharmaceutical firms, such as Bayer, Novartis, and Merck & Co. As a non-executive chairman, Ornskov will oversee Centogene's strategy development, US expansion, and strategic M&A. 

Apr 02, 2019

Steve Fletcher, Tim Dwyer, Joseph Fitchett, Stephen Crossland, Andrew Wheeler

Mologic has announced the opening of a US subsidiary and key appointments for its US and United Kingdom sites.

The firm announced Steve Fletcher as president and chief commercial officer of Mologic Inc. and head of the firm's US headquarters located just outside of Boston, Massachusetts.

Fletcher has more than 25 years of experience in leading marketing, product, and business operations for global healthcare companies, including 3M, Thermo Fisher Scientific, and GC America.

Mologic also appointed Tim Dwyer as its chief technology officer. Dwyer is a fellow of the Royal Society of Biology with more than 19 years of experience in the design and development of diagnostic devices on multiple immunoassay platform technologies.

The firm appointed Joseph Fitchett as its chief medical officer and head of global health to support the expansion of its UK facilities. In his previous role as a program officer at the Bill & Melinda Gates Foundation, Fitchett advanced the foundation’s bilateral partnerships with European Union donors, including advancing the manufacturing capacity of yellow fever vaccine and infectious disease surveillance and control, at the Institut Pasteur in Dakar.

In the US, Mologic also appointed Stephen Crossland as vice president of sales and business development and Andrew Wheeler as R&D manager.

Apr 01, 2019

Marc Williams, Karen Gripp, Dietrich Matern, Michael Murray, Cynthia Powell, Heidi Rehm

Marc Williams has been announced as president-elect of the American College of Medical Genetics and Genomics. He is the director of the Geisinger Genomic Medicine Institute. Prior to joining Geisinger in 2012, he was the director of Intermountain Healthcare's Clinical Genetics Institute. Williams is a board-certified pediatrician and holds an MD as well as an undergraduate degree in chemistry from the University of Wisconsin-Madison.

Williams and five others have also been elected to the ACMG's board of directors for a six-year term that starts this month. The other new directors are Karen Gripp, chief of the Division of Medical Genetics at the Nemours/Alfred I. duPont Hospital for Children and medical director of its molecular diagnostics laboratory; Dietrich Matern, chair of the Division of Laboratory Genetics and Genomics in the Department of Laboratory Medicine and Pathology at the Mayo Clinic; Michael Murray, director of clinical operations in the Center for Genomic Health at Yale University School of Medicine; Cynthia Powell, director of the medical residency program and medical director of the UNC Hospitals Cytogenetics Laboratory; and Heidi Rehm, chief genomics officer at Massachusetts General Hospital and medical director of the Broad Institute's clinical laboratory.

Mar 29, 2019

Amol Chaubal

Quanterix said this week that it has appointed Amol Chaubal as CFO, effective April 12, 2019. He replaces Joseph Driscoll, who is stepping down as CFO. Chaubal joins Quanterix from medical device firm Smith & Nephew, where he currently serves as CFO of global operations. Prior to Smith & Nephew, he served as corporate VP and head of finance for Parexel's CRS business, and has also held various roles at Novartis, including CFO North America – Vaccines & Diagnostics.

Mar 28, 2019

Bob Petrou

NantHealth has removed the "interim" tag from CFO Bob Petrou, company CEO Patrick Soon-Shiong disclosed today in a conference call with reporters and financial analysts. Petrou joined NantHealth in September following the resignation of former CFO Paul Holt.

Mar 27, 2019

Lloyd Sanders

Epic Sciences has appointed Lloyd Sanders as president and CEO. He will be replacing Murali Prahalad, who is stepping down and has been appointed to the board of directors. Sanders joins the firm with 20 years of diagnostic and pharmaceutical industry experience. He previously served as president of Myriad Genetics' oncology segment. Prior to Myriad, Sanders served as chief operating officer at Dey Pharma. Before Dey Pharma, Sanders worked at Genta, where he acted as VP of marketing and later COO.

Pages